SEI Investments’s Arcutis Biotherapeutics ARQT Stock Holding History

SEI Investments’s Portfolio ARQT Stock Details ARQT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3M	Sell	114,253 -91,888	-45%	-$2.14M	﹤0.01%	1757
2026 Q1	$4.86M	Buy	206,141 +101,855	+98%	+$2.6M	﹤0.01%	1552
2025 Q4	$3.03M	Buy	104,286 +78,423	+303%	+$2.01M	﹤0.01%	1649
2025 Q3	$488K	Buy	25,863 +13,764	+114%	+$217K	﹤0.01%	2242
2025 Q2	$170K	Sell	12,099 -27,251	-69%	-$382K	﹤0.01%	2598
2025 Q1	$615K	Buy	+39,350	New	+$554K	﹤0.01%	2076
2023 Q2	–	Sell	-273,599	Closed	-$3.01M	–	2672
2023 Q1	$3.01M	Buy	+273,599	New	+$3.96M	0.01%	1432
2022 Q4	–	Sell	-172,848	Closed	-$3.3M	–	2531
2022 Q3	$3.3M	Buy	172,848 +28,910	+20%	+$655K	0.01%	1294
2022 Q2	$3.07M	Buy	+143,938	New	+$2.95M	0.01%	1349

Other funds holding ARQT

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

SEI Investments's ARQT Position: Q2 2026 in Review

SEI Investments reduced its Arcutis Biotherapeutics (ARQT) stake by 45% in Q2 2026, selling an estimated $2.14M and leaving 114,253 shares worth $3M. The position accounts for ﹤0.01% of the portfolio, ranked #1757.

SEI Investments first reported a position in ARQT in Q2 2022 and has held it in 9 quarters since. The position peaked at $4.86M in Q1 2026. 272 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

SEI Investments held 114,253 shares of Arcutis Biotherapeutics worth $3M as of Q2 2026.
SEI Investments sold 91,888 Arcutis Biotherapeutics shares in Q2 2026, an estimated $2.14M.
Arcutis Biotherapeutics made up ﹤0.01% of SEI Investments's portfolio in Q2 2026, its #1757 holding.
SEI Investments first reported a position in Arcutis Biotherapeutics in Q2 2022 and has held it in 9 quarters since.
SEI Investments's Arcutis Biotherapeutics position peaked at $4.86M in Q1 2026.
272 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on SEI Investments's 13F filing for Q2 2026, filed 14 Aug 2026.